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ABSTRACT  
Despite the well established benefits of currently approved delayed release proton pump 
inhibitors (PPIs) in the treatment of acid related diseases, the unmet needs are still present 
and although often frustrating, they challenge clinicians. The unmet needs relate to the lack 
of complete control of acid secretion with oral PPI administration in the management of 
patients with gastro-oesophageal symptoms. These substantial groups of patients, who do 
not respond completely to standard doses of PPIs, are non-responders; and their lack of 
response should be considered as PPIs failure. Several mechanisms could explain PPI 
failure: differences in pharmacokinetics, PPIs formulation, dosing time and diet, 
noncompliance, transient lower oesophageal sphincter relaxations (TLESRs), oesophageal 
hypersensitivity, and nocturnal acid breakthrough. To increase QoL of these patients and 
avoid multiple medical consultations and unnecessary investigations, we have to go one step 
forward, to use combine therapy or look towards new treatments beyond acid suppression.  
 
 
Key words: unmet needs, acid inhibition, proton pump inhibitors (PPIs), gastroesophageal 
reflux disease (GERD), nonerosive reflux disease (NERD), Barrett’s oesophagus, nocturnal 
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INTRODUCTION 
The development of the PPIs and their introduction in the late 1980s enabled significant 
improvement in the management of various acid-related upper gastrointestinal disorders. 
Because of their efficiency, minimal side effects and general safety for long-term treatment, 
today they are the most common prescribed drugs in the treatment of acid-peptic diseases. A 
meta-analysis of 43 studies on gastro-oesophageal reflux disease (GERD), including 7635 
patients, demonstrated a more complete and twice as fast esophagitis healing and heartburn 
relief with PPIs vs. histamine receptor antagonists (H2RAs). 1 
However, in last ten years many articles regarding the unmet needs of acid suppression 
have been published indicating that currently available PPIs have notable limitations and are 
still far from the ideal antisecretory compound. The unmet needs relate to the lack of 
complete control of acid secretion with oral PPIs administration in the management of 
patients with gastro-oesophageal symptoms, non-variceal upper gastrointestinal bleeding, 
nonsteroidal anti-inflammatory drugs (NSAIDs) and GIT mucosa injury, and Helicobacter 
pylori infection. 2-5  
The question is whether the current PPIs still have hidden potential or unmet clinical needs 
require to be addressed with newer agents capable of achieving rapid and long-lasting acid 
suppression?6 
 
Differences in PPIs pharmacokinetics 
Differences in PPIs pharmacokinetics, bioavailability, elimination half-life and metabolism 
have been observed and could be the answer for the differences in clinical outcomes.7 PPI 
products currently available on the market (omeprazole, esomeprazole, lansoprazole, 
pantoprazole, rabeprazole) all contain basic structural framework, 2-
pyridylmethylsulfinylbenzimidazole pharmacophore, varying only in the specific side ring 
substitution. Tenatoprazole, a new PPI, has an imidazopyridine ring. 
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PPIs pKa of about 4.0 enables their accumulation only in the acidic secretory canaliculus of 
the stimulated parietal cell, where they are converted into thiophilic intermediates that bind to 
cysteine sulfhydryl groups on the luminal aspect of the proton pump to form covalent 
disulfide bonds. This covalent inhibition of the enzyme by the thiophilic sulfenamide results in 
a specific and long-lasting impairment of gastric acid secretion. The antisecretory effect of 
the drugs reflects their short plasma half-life (ranging from 1 to 1.5 hours), the number of 
active pumps during that time, and the recovery of pumps following biosynthesis and reversal 
of inhibition.8 Tenatoprazole, a new PPI that has a 5- to 7-fold longer elimination half-life than 
other current PPIs, could be potentially more useful for the treatment of GERD and NAB.4,9 
One of the latest comparisons of pharmacodynamic and pharmacokinetic profiles of 
tenatoprazole and esomeprazole has shown significantly greater and more prolonged dose-
dependent 24-h and nocturnal acid suppression with S-tenatoprazole-Na than esomeprazole. 
S-tenatoprazole-Na may provide greater clinical efficacy compared with current PPIs for 
patients with ineffective once-daily therapy.10 
 
PPIs formulation 
PPIs are often referred as prodrugs, although they do not require enzymatic activation. They 
are acid- labile, weak bases formulated as delayed-release enteric-coated preparations. 
Enteric coating is protecting PPIs from premature acid degradation in the stomach so that 
absorption can occur in the proximal small intestine. Because of that, there is a delay in 
absorption and onset of their antisecretory effect.11 Lansoprazole fast disintegrating tablet 
(LFDT), so called “patient-friendly” and more convenient formulation of lansoprazole which 
can be taken with or without water, was the first PPI to be made available as an orally 
disintegrating tablet (ODT).12  Unfortunately, no significant differences  in symptom relief 
between lansoprazole ODT and esomeprazole were reported in patients with non-erosive 
reflux disease.13 Few years ago, immediate-release omeprazole has been introduced. It 
consists of pure, non enteric-coated omeprazole powder along with sodium bicarbonate, 
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which acts as a buffer against gastric acid degradation. The absence of an enteric coating 
facilitates rapid absorption. Studies have shown that immediate-release omeprazole when 
compared to delayed-release omeprazole, has a higher mean peak plasma concentration 
(C(max) 1019 ng/mL vs 544 ng/mL)) and a significantly shorter mean time to reach significantly 
shorter tmax (25 minutes vs 127min).
14 In the management of nocturnal acid breakthrough 
(NAB), repeated once-daily (bedtime) dosing with immediate-release omeprazole produced 
significantly better results than repeated once daily (pre-dinner) or twice-daily dosing with 
delayed-release pantoprazole. Twice daily dosing (prebreakfast and bedtime) with 
immediate-release omeprazole 20 and 40mg achieved the best night-time control of gastric 
acidity.15 
 
Dose 
There are differences in PPIs bioavailability after single and repeated dose. Early complete 
heartburn relief with proton pump inhibitors for the entire day occurs in only 30% of patients 
after their first PPI dose and in 9% of patients after placebo. Although PPIs might provide 
benefit from the first day of therapy, most patients will not have symptom relief with 1 or 2 
days of PPI therapy.16 The first published comparative pharmacodynamic trial comparing 
standard doses of esomeprazole, lansoprazole, omeprazole, pantoprazole and rabeprazole 
has shown that esomeprazole at the standard dose of 40 mg once daily provided more 
effective control of gastric acid at steady state than standard doses of other PPIs in patients 
with symptoms of gastroesophageal reflux disease.17 The bioavailability of rabeprazole on 
day 1 is greater than with other PPIs, and this may translate into faster onset of symptom 
relief for patients with gastro-oesophageal reflux disease. On the other hand, the 
bioavailability of esomeprazole increases 3-fold at day 5, and it has been shown that on day 
5, esomeprazole provided significantly more effective control of gastric acid than other PPIs. 
The exact clinical significance of these observations remains to be determined.18 Differences 
in hepatic metabolism of PPIs due to cytochrome P450 2C19 genetic polymorphisms may 
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influence clinical outcomes. In Helicobacter pylori eradication, a significantly lower 
eradication rate was seen in extensive metabolisers with omeprazole and lansoprazole but 
not with rabeprazole. The oesophagitis healing rate was lower in extensive metabolisers with 
lansoprazole but not with rabeprazole.7 
 
Nutritional intake and food timing 
There is sufficient evidence to support the relationship between being obese/overweight and 
GERD, expressed as specific symptoms and endoscopic features. Furthermore, available 
evidence suggests that controlled weight loss is able to induce a significant improvement in 
GERD symptoms and/or in GERD clinical-endoscopic manifestations. It is a common belief 
that some foods may induce or worsen GERD symptoms. In daily clinical practice, this belief 
leads to advising patients to avoid the suspect foods. Since GERD symptoms are most 
commonly reported postprandial, the role of diet components in inducing symptoms has been 
suggested. However, different and conflicting results exist in the literature for identifying the 
most “refluxogenic” foods. Clinical studies have shown a decrease in LES pressure and an 
increase in esophageal acid exposure in response to the ingestion of food rich in fats, 
chocolate and carminatives. Also, studies demonstrated that fried foods, spicy foods and 
alcohol are the most common precipitating factors of heartburn.19  According to the study of 
El-Serag et al. there is a positive association between high fat intake, and GERD symptoms 
as well as erosive esophagitis, while a high-fibre diet seemed to reduce reflux symptoms. 
The effects of fat on GERD symptoms and erosive esophagitis were dependent on BMI since 
this was statistically significant only in overweight individuals.20 While some authors have 
suggested that alcohol is an independent risk factor for GERD-related symptoms, others 
have not found such a relationship. Similar observation was for ingestion of coffee; while 
intraesophageal infusion of coffee in patients with acid sensitivity may induce heartburn, two 
large epidemiological studies have found no association between coffee drinking and 
GERD.21,22 
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Effectiveness of a PPI is also dependent on food timing and food intake. As gastric acid 
secretion is maximally stimulated by food ingestion, maximal PPI efficacy should be achieved 
when they are taken before a meal. Hatlebakk’s study has shown an advantage in daytime 
intragastric pH control when a morning dose of omeprazole or lansoprazole were taken 
before breakfast compared with no breakfast. Therefore, intake of medication in relation to 
meals, specially may be important to optimize their effect and avoid therapeutic failure.23 
PPIs are most often prescribed for intake in the morning and in most individuals, once-daily 
dosing is sufficient to produce the desired level of acid inhibition, and a second dose, which 
is occasionally necessary, should be administered before the evening meal.2  
 
WHAT DO WE KNOW ABOUT UNMET NEEDS?  
 
Gastro-oesophageal reflux disease 
GERD is defined as a condition that develops when the reflux of stomach contents causes 
troublesome symptoms, with or without mucosal damage, and/or complications.24 A 
systematic review of the epidemiology of GERD has demonstrated 10-20% prevalence, 
defined by at least weekly heartburn and/or acid regurgitation, in the Western world and less 
than 5% in Asia. The incidence in the Western world is approximately 5 per 1000 person 
years.25 Although, the proton pump inhibitors are highly effective for the majority of patients 
with erosive oesophagitis and considered the mainstay treatment for GERD, significant 
therapeutic challenges still exist,. Surveys among primary-care physicians (PCPs) indicate a 
number of areas of controversy and confusion related to the management of GERD. It was 
found that most PCPs prescribe PPIs for GERD without prior authorization and without first 
using an H2RA and many of them give an H2RA with once-daily PPI treatment for patients 
with nocturnal heartburn. The appropriate advice regarding the importance of PPIs use and 
food intake was in less than 64% of patients.26 The conclusion of recently published review 
from Yuan and Hunt was that a substantial number of patients fail to respond adequately to 
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once or even twice daily PPI and that there is no standard definition of PPI failure in GERD 
as well as a universally accepted definition for treatment success. 27 
The prevalence of PPI failure differs from patients with nonerosive reflux disease (NERD) 
and those with erosive oesophagitis. PPIs provide a more modest therapeutic gain in 
patients with NERD as compared with those witherosive oesophagitis. Total response rates 
at 4 weeks were significantly higher for patients with erosive oesophagitis compared with 
NERD (56% vs. 37%).28 Studies in the different phenotypic presentations of GERD suggest 
that the overall prevalence of PPI failure is approximately 30%.29 Meta-analysis of 
symptomatic GERD patients found that in about two-thirds of patients, reflux symptoms are 
not adequately controlled after the first dose of a PPI, and nearly 50% patients still suffer 
symptoms 3 days later.30 
 
Nonerosive reflux disease 
NERD is the most common form of GERD. In a primary care setting up to 70% of patients 
with typical symptoms of GERD have NERD. The closest entity to NERD that is examined by 
available epidemiologic studies is defined by the presence of GERD symptoms in the 
absence of esophageal erosions or Barrett’s esophagus.32 NERD is often characterized with 
troublesome symptoms that affect the quality of life similar to that reported by patients with 
erosive oesophagitis. GERD patients with NERB are relatively refractory to the 
pharmacodynamic effects of proton pump inhibitors on the postprandial integrated gastric 
acidity,33 suggesting that their symptoms may be generated by different mechanisms than 
acid as in erosive oesophagitis. 
The proportion of NERD patients responding to a standard dose of PPIs is approximately 
20–30% lower than what has been documented in patients with erosive oesophagitis.29,31,31 
Progression to erosive gastroesophageal reflux disease (ERD) occurs in about 5% of NERD 
cases per year, despite standard therapy. Factors that are consistently and independently 
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influencing this progression are smoking and the lack of a continuous PPI therapy during the 
follow-up period.34 
Recently, biopsies established that subjects with heartburn and PPI-responsive NERD, like 
those with erosive esophagitis, have lesions within the esophageal epithelium known as 
dilated intercellular space (DIS), suggesting that DIS might be involved in development of 
persistent symptoms.35  Dexlansoprazole MR a novel, modified-release formulation of 
dexlansoprazole, which incorporates dual delayed- release technology designed to prolong 
the serum concentration- time profile, and thus provides extended acid-suppression, has 
been recently assessed in NERD patients.37 In 4-week, double-blind, placebo-controlled 
study with 947 NERD patients dexlansoprazole 30 mg/day for 4 weeks was shown to be 
superior to placebo in providing 24-hour heartburn-free days and nights (54.9% vs. 17.5% 
and 80.8% vs. 51.7%, respectively).38 
 
Erosive oesophagitis  
Erosive oesophagitis accounts for about 20-30% of patients with GERD demonstrates 6-15% 
of PPI (once daily) treatment failure. Patients with more severe grades of erosive 
oesophagitis have demonstrated a higher PPI failure rate than those with less severe 
disease.29  Nonresponse of erosive esophagitis increases with severity of erosive esophagitis 
grading. The nonhealed rate for Los Angeles grade C and grade D erosive esophagitis on 
standard dose PPIs suggests that approximately 40% of moderate (C) and 51% severe (D) 
erosive esophagitis were unhealed after 4 weeks and 18% of C and 27% of D at 8 weeks.39 
 
Barrett’s oesophagus 
The prevalence of Barrett’s oesophagus is 6–12% of all patients who present for endoscopy 
with GERD-related symptoms, and 0.25–3.9% in unselected cases undergoing upper 
endoscopy.40 Barrett’s esophagus is considered to follow a progression from intestinal 
metaplasia to low-grade dysplasia (LGD) to high-grade dysplasia (HGD) and finally to 
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esophageal adenocarcinoma in a subset of patients. Conservative management, involving  
symptom control and periodic endoscopic surveillance to exclude progressive disease, is 
recommended for patients with Barrett’s esophagus without evidence of dysplasia or cancer. 
Lifestyle modifications can be helpful to increase esophageal acid clearance and decrease 
the incidence of reflux events.41 
 
Atypical symptoms 
GERB can be presented with atypical or extraoesophageal symptoms, including asthma, 
unexplained chronic cough, laryngitis, oropharyngitis, nocturnal wheeze, chronic sore throat, 
dental erosions, and noncardiac chest pain. Empiric trial using proton pump inhibitors is still 
the recommended initial approach to those suspected of having reflux as the cause for 
extraesophageal symptoms such as asthma, chronic cough or laryngitis, although, recent 
randomized placebo-controlled studies have been disappointing in showing benefit of acid 
suppressive therapy.42-46 
 
Nocturnal acid breakthrough 
NAB has been arbitrarily defined as the presence of gastric pH below 4 for at least 1h during 
the night – in patients on PPI therapy. This is physiological phenomenon that has been 
observed in 75% of all individuals (GERD patients as well as healthy subjects) taking PPI 
twice a day.45 Recent US survey of GERD patients taking PPIs clearly emphasized that over 
80% of the patients reported night symptoms during the previous 30 days and 23.4% 
described symptoms as severe or very severe.46 In total, 22% of responders were on PPI 
b.i.d. and 42% supplemented prescribed PPIs by OTC PPIs, H2RAs, or antacids. Among 
patients on PPI b.i.d., 39.1% increased the dose due to poor symptom control at night.47 
Increased night time acidity leads to more severe GERD symptoms and could be associated 
with obstructive sleep apnea.48 Due to the short plasma half life (1-2 h) delayed release PPIs 
do not have effect on acid suppression 5 hours after evening dose because there is no drug 
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available to inhibit acid pumps synthesized during the night time hours so intragastric pH 
may remain less than 4 for up to a third of the night 49 Therefore, acid secretion after midnight 
is not controlled even with the most aggressive acid-suppressive therapy. Therapeutic 
approach that included the addition of histamine-2 receptor antagonist (H2RA) at bedtime 
was introduced and quickly adopted. In summary, the presence of NAB in patients treated 
with a PPI is a physiological phenomenon that has yet to demonstrate an association with 
clinical parameters, such as symptoms or erosive esophagitis.  
 
Rebound acid hypersecretion 
Rebound is defined as an increase in gastric acid secretion above pre-treatment levels 
following discontinuation of antisecretory therapy. Rebound is clinicaly important because it 
seems that it contributes to the recurrence of GERD.50 There are four mechanisms to explain 
rebound : up regulation of H2-receptors, hypergastrinaemia-stimulating histamine release by 
enterochromaffin-like (ECL) cells, increase of parietal cell mass and up regulation of H+/K+-
ATPase activity.51 Increased gastric acid secretion is well described after stopping the long-
term use of histamine H2- receptor antagonists,52,53 but its occurrence after the prolonged 
use of PPIs is controversial, it seems that there is no strong evidence for a clinically relevant 
increased acid output after PPI therapy is stopped.51-53  Three uncontrolled trials 
nevertheless suggested an increase in acid secretory capacity in H. pylori negative subjects 
after 8 weeks of treatment.54-56 In this situation rebound hypersecretion after attempting to 
stop the PPI, could result in GERD symptoms worsening and therefore resulting in 
prolongation of the PPIs use.52 Perhaps the advice should be to never abruptly stop PPI 
therapy but to always step down to half strength and then to intermittent therapy if full 
symptom control is obtained. Whether on-demand therapy may also lead to rebound is 
unknown, but deserves to be evaluated.2 
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Quality of life (QoL) 
Heartburn and acid regurgitation are the cardinal symptoms of GERD.57 It is well known that 
severity and frequency of these symptoms are associated with impaired QoL.58,59 Generic 
measurements have shown that GERD patients even have a lower QoL than patients with 
chronic ischemic heart disease.60 
Today, PPIs as the most commonly prescribed drugs in case of GERD play an important role 
in patients QoL. The German prospective cohort study (ProGERD) with over 6000 GERD 
patients determined that the quality of life of individuals with reflux disease, in terms of both 
physical and psychosocial aspects of wellbeing, was significantly lower than that of the 
general population. Problems with eating and drinking, vitality and pain were defined as most 
significant to impair the QoL. However, it was shown that this can easily be relieved or even 
eliminated within a short period of time (2 weeks) by treatment with esomeprazole, 
irrespective of whether the patient is suffering from non-erosive or erosive GERD or Barrett's 
oesophagus.59 Three years later, results of the first study that involved endoscopy in the 
general population, suggest that the presence or absence of oesophagitis does not appear to 
predict impairment of QoL.60 Recently, one study demonstrated that the QoL associated with 
the reflux oesophagitis and NERD subtypes may be more related to psychological factors 
(anxiety and depression) than to symptom severity.61 
 
BEYOND ACID SUPPRESION: MENAGEMENT OF FAILURE 
 
Logical step forward would be the next generation of drugs, which suppress gastric acidity. A 
number of new drugs are currently being investigated. Potassium-competitive acid blockers 
(P-CABs) are potassium competitive inhibitors of the ATPase.5 Considering the main 
differences in the mechanism of action between P-CABs and PPIs, a clinically relevant fact is 
that P-CABs have a full effect after the first dose. Potassium competitive antagonists and 
gastrin (CCK2) receptor antagonists reached clinical testing, but did not fulfil all clinical 
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expectations. Dual approach, using PPIs in combination with TLESR- targeted agents, would 
reduce the time that patients need to achieve heartburn control and minimize possible ceiling 
effect of PPI therapy.62 Since PPIs have no effect on TLESR, new add-on medication 
therapies will be of great interest for pharmaceutical companies in the future. 
The type B gamma-aminobutyric agonists (GABA (B)) receptor agonists are new 
medications, which are currently undergoing clinical trials to establish their potential to 
reduce TLESR and reflux episodes, increase basal lower esophageal sphincter pressure and 
reduce swallowing. Limitations are small human phase 1 and 2 trails, and significant side-
effects, particularly those affecting liver and central nervous system. Discovery of analogues 
with an improved side effect profile is warranted. 
The metabotropic glutamate receptor (mGluR) antagonists have similar mechanism of action 
as GABA (B) agonists. Their research is currently in the phase of animal studies, except for 
one human proof-of-concept study.63 
Endoscopic antireflux procedures were introduced with great enthusiasm at the beginning of 
this century but after all a recent AGA Institute medical position statement recommended that 
“current data suggest that there are no definite indications for endoscopic therapy for GERD 
at this time”. 64..   
 
CONCLUSION 
 
The proton pump inhibitors are a group of drugs that reduce the secretion of gastric acid, and 
are highly successful in treating of patients suffering from acid related diseases. 
Unfortunately, there are still significant number of patients that have persistent dyspeptic 
symptoms and decrease QoL despite use of PPI’s. The unmet needs of PPI’s relate to the 
lack of complete control of acid secretion with oral PPI administration in the management of 
patients with gastro-oesophageal symptoms, non-variceal upper gastrointestinal bleeding, 
NSAID gastrointestinal injury and Helicobacter pylori. To increase QoL of these patients and 
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avoid multiple medical consultations and unnecessary investigations, we have to go one step 
forward, to use combine therapy or look towards new treatments beyond acid suppression. 
Beside the acid suppression, there are different potential targets in patophysiological 
mechanisms of GERD and acid related diseases where we can act in order to accomplish 
the support to those patients. The role of those new medications and endoscopic procedures 
remains to be proved, before placing as an add-on therapy to PPIs.  
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